Results 11 to 20 of about 54,678 (274)
Regulation of Tumor Angiogenesis by EZH2 [PDF]
SummaryAlthough VEGF-targeted therapies are showing promise, new angiogenesis targets are needed to make additional gains. Here, we show that increased Zeste homolog 2 (EZH2) expression in either tumor cells or in tumor vasculature is predictive of poor ...
Rouba Ali-Fehmi +77 more
core +6 more sources
Regulation and role of EZH2 in cancer.
[[abstract]]Polycomb repressive complex 2 (PRC2) is the epigenetic regulator that induces histone H3 lysine 27 methylation (H3K27me3) and silences specific gene transcription.
Yamaguchi, H;Yamaguchi, H;洪明奇*
core +3 more sources
EZH2-dependent myelination following sciatic nerve injury
Demyelination and remyelination have been major focal points in the study of peripheral nerve regeneration following peripheral nerve injury. Notably, the gene regulatory network of regenerated myelin differs from that of native myelin.
Hui Zhu +10 more
doaj +2 more sources
The enhancer of zeste homologue 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 that catalyzes methylation of histone H3 lysine 27 (H3K27).
Wenliang Wang (1233804) +16 more
core +3 more sources
EZH2 in Myeloid Malignancies [PDF]
Our understanding of the significance of epigenetic dysregulation in the pathogenesis of myeloid malignancies has greatly advanced in the past decade. Enhancer of Zeste Homolog 2 (EZH2) is the catalytic core component of the Polycomb Repressive Complex 2 (PRC2), which is responsible for gene silencing through trimethylation of H3K27. EZH2 dysregulation
Jenny Rinke +4 more
openaire +3 more sources
Epigenetic regulation is a novel approach to cancer treatment. Inhibition of enhancer of zeste homolog 2 (EZH2) is a method to provide targeted epigenetic regulation. Tazemetostat is a first-in-class targeted epigenetic regulator that specifically inhibits EZH2.
Straining, Rachael, Eighmy, William
openaire +2 more sources
Targeting EZH2 in cancer [PDF]
Recent genomic studies have resulted in an emerging understanding of the role of chromatin regulators in the development of cancer. EZH2, a histone methyl transferase subunit of a Polycomb repressor complex, is recurrently mutated in several forms of cancer and is highly expressed in numerous others.
Kimberly H, Kim, Charles W M, Roberts
openaire +2 more sources
The noncanonical role of EZH2 in cancer [PDF]
AbstractEnhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2). Dysregulation of EZH2 causes alteration of gene expression and functions, thereby promoting cancer development. The regulatory function of EZH2 varies across different tumor types.
Jinhua Huang +6 more
openaire +2 more sources
Ezh2-mediated epigenetic repression may partially influence exhaustion.
(A) Experimental setup. Control CD45.1+ (wild-type, “WT”) and Ezh2-deficient CD45.1.2+(Ezh2fl/flCd4Cre+, “Ezh2 KO”) CD8+ P14 T cells were cotransferred into congenically distinct CD45.2+ recipient mice prior to infection with LCMV-Cl13; recipient mice ...
Lara Labarta-Bajo (9096773) +14 more
core +1 more source
Targeting EZH2 as cancer therapy [PDF]
Abstract Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2) that mediate repression of target genes by trimethylation of Lys27 in histone 3 (H3K27me3). Given the reported roles of EZH2 in cancer, it is perhaps not surprising that targeting EZH2 in cancer therapy has become a hot research ...
Shunsuke Hanaki, Midori Shimada
openaire +2 more sources

